CBD Insomnia Trial Advances Toward Over-the-Counter Approval

A pharmaceutical cannabidiol capsule has passed the interim checkpoint of what its maker calls the world’s largest clinical trial of CBD for insomnia, clearing the study to run to completion — and putting an Australian biotech in position to sell the first CBD medicine approved for over-the-counter use in the country.

On June 24, 2026, Avecho Biotechnology, a Melbourne-based drug-delivery company listed on the Australian Securities Exchange, said an independent data monitoring board had reviewed the first results from its Phase III insomnia trial and recommended the study continue to its full planned enrollment of 519 participants. The board, the only group with access to the unblinded data, found the trial had met the efficacy and safety thresholds written into its protocol.

The result is an encouraging signal, not a finding. The interim analysis drew on the first 244 participants, who took a nightly 75mg or 150mg dose of CBD or a placebo over eight weeks. On the company’s account, the data satisfied the protocol’s pre-specified efficacy and safety criteria, with no serious adverse events recorded. But the study remains blinded, Avecho itself has not seen which participants received what, and the full data set will not be unlocked until the trial finishes next year. None of it has been peer-reviewed.

What the interim result shows — and what it doesn’t

The trial is a multi-centre, randomised, double-blind, placebo-controlled study running across Australian sites, with two independent primary endpoints: the Insomnia Severity Index, a validated symptom questionnaire, and subjective sleep efficiency, a measure of time asleep against time in bed. The monitoring board did not declare the drug effective. It confirmed that the treatment effect and variability seen so far track the assumptions the study was built on, so the trial can finish at its original size rather than needing more patients. That is a de-risking milestone, not proof of efficacy.

The distinction matters because the controlled evidence for CBD as a sleep aid is thin. A 2024 randomised pilot trial of 150mg nightly CBD in people with moderate-to-severe insomnia — 15 on the drug, 15 on placebo — found no difference from placebo on insomnia severity or self-reported sleep, though the CBD group reported better well-being and showed a modest gain in objectively measured sleep efficiency. Small, mostly null trials like that one are why a properly powered study of several hundred patients would be a real addition to the cannabinoid sleep literature, where self-reported benefit has consistently outrun controlled evidence.

Avecho’s capsule pairs synthetic CBD with a proprietary formulation, derived from vitamin E, that the company says improves how much of the poorly absorbed compound reaches the bloodstream — roughly a fourfold increase over Epidiolex in dog studies, on its own data. Oral CBD’s low and variable bioavailability has long complicated consistent dosing, so absorption is a plausible point of differentiation, but the animal comparison has not been independently confirmed in humans.

The regulatory prize

The commercial logic rests on a quirk of Australian rules. In February 2021, the Therapeutic Goods Administration down-scheduled low-dose CBD — up to 150mg a day, at least 98% pure — from prescription-only to pharmacist-only, in theory allowing over-the-counter sales. In practice, no product has ever cleared the agency’s registration bar, so there is still nothing on pharmacy shelves. Australians who use CBD get it on prescription, through channels reserved for unapproved medicines.

If Avecho’s trial succeeds and the product is registered, it would be the first CBD medicine approved for over-the-counter sale in Australia. The company argues that registration would also close the prescription route to competitors for the same use, because the unapproved-medicine pathways operate only where no registered product exists for that indication — an effective first-mover monopoly. That reading is the company’s, and it turns entirely on the full trial confirming the interim signal.

The prospect has already drawn a major partner. In 2025, Avecho licensed the Australian rights to Sandoz, the Swiss generics company, for US$3 million upfront, up to US$16 million in milestones and tiered royalties of 14% to 19%. Avecho puts the addressable Australian over-the-counter market above US$125 million a year.

What to watch next

Avecho says it now plans to approach the US Food and Drug Administration and other regulators. The timing is notable: the FDA’s 2026 revised draft guidance foregrounds the option of approving a drug on a single adequate and well-controlled trial backed by confirmatory evidence, rather than the two pivotal trials long treated as the default. The guidance is not final and does not change the underlying legal standard, but it signals more flexibility for sponsors with one strong study — which is what Avecho is trying to build. The company frames its capsule as a potential second pharmaceutical CBD after Epidiolex, part of a broader effort to move cannabinoids through formal drug-approval pathways rather than the unregulated wellness market.

For now, the claims rest on an interim look at half the data. CEO Paul Gavin captured the shift in a company statement: “For three years, our focus has been assessing whether this product works. From here, we are planning the business on the assumption that it does.” The assumption holds only if the full 519-patient readout, due next year, reproduces the early signal on endpoints that smaller trials have repeatedly failed to move.